Fed. Circ. Eyes Stanford Transplant Test IP Eligibility

By Khorri Atkinson (June 10, 2022, 9:10 p.m. EDT) — Two federal circuit judges appeared not fully convinced on Friday that three Stanford University patents were licensed to CareDx Inc., developer of commercial tests for transplant rejection kidney, are valid under the Alice decision of the Supreme Court of the United States.

Judges expressed skepticism as lawyers for CareDx and Stanford insisted that a federal judge in Delaware in September erroneously concluded that the patents were not eligible for protection under the criteria set out in the Alice Corp decision. vs. Supreme Court 2014 CLS Bank. The judges held that abstract ideas are not patentable in the absence of an additional inventive concept transforming them into something patentable.

U.S. Patents No. 8,703,652;…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!



Comments are closed.